Related references
Note: Only part of the references are listed.Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action
Jean-Marie Nicolas et al.
EPILEPSIA (2016)
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies
Elinor Ben-Menachem et al.
NEUROLOGY (2016)
A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures
Pavel Klein et al.
EPILEPSIA (2015)
Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability
Andreas Schulze-Bonhage et al.
PATIENT PREFERENCE AND ADHERENCE (2015)
Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial
Victor Biton et al.
EPILEPSIA (2014)
Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial
Philippe Ryvlin et al.
EPILEPSIA (2014)
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties
Michel Gillard et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Lamotrigine extended-release as adjunctive therapy for partial seizures
D. K. Naritoku et al.
NEUROLOGY (2007)
Share Paper
